How can we improve the successful identification of patients suitable for CAR-T cell therapy?-Reference-Cited by-同舟云学术

How can we improve the successful identification of patients suitable for CAR-T cell therapy?

Published:2024-09-11 Issue: Volume: Page:1-16
ISSN:1473-7159
Container-title:Expert Review of Molecular Diagnostics
language:en
Short-container-title:Expert Review of Molecular Diagnostics

Author:

Feng Youqin¹²³⁴,Wu Longyuan¹²³⁴,Gu Tianning¹²³⁴,Hu Yongxian¹²³⁴,Huang He¹³⁴

Affiliation:

1. Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

2. Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, Zhejiang, China

3. Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China

4. Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, China

Funder

National Natural Science Foundation of China

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737159.2024.2399152

Reference114 articles.

1. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

2. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma;Ernst M;Cochrane Database Syst Rev,2021

3. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

4. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

5. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT;Spyridonidis A;Leukemia,2012